{"success":true,"data":{"pressRelease":{"id":"56365","rtpr_id":"nGNEmHSCb","ticker":"COSM","exchange":"NASDAQ","all_tickers":["COSM"],"title":"Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories","author":"Globe Newswire","published_at":"2026-06-05T13:25:00.313Z","article_body":"Science-backed, USDA and EU-certified, whole olive tree supplement for two\nmajor wellness categories — rapidly growing global market projected to\nexceed $33 billion\n* Oliv18™ expands the 18 Series with a USDA and EU organic certified, 100%\nsolvent-free, whole olive polyphenol formulation from the Moroccan Saharan\ndesert\n* Hydroxytyrosol — the key active in Oliv18™ — is the highest ORAC\npolyphenol\n* A single 250 mg daily dose meets EFSA's 5 mg/day hydroxytyrosol minimum dose\nfor protection against LDL oxidation\n* A single daily dose equivalent to approximately 11 teaspoons of good quality\nextra virgin olive oil — compared to an average of half a teaspoon per day\nin the U.S.\n* Targeting the multibillion cardiovascular health and antioxidant markets,\ninitially in the United States and globally thereafter — within a combined\nglobal market landscape projected to exceed $33 billion by 2035\nCHICAGO, June 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.\n(https://www.globenewswire.com/Tracker?data=XjivXZ2iXwdVaNMLztXns3ZQYWrVdoQsE5h2TGn-I4CNkJE4fWFyLPRemCeOIHc400Zrqfpt5vFr4x5cyEsMjmYXjtZ2-9RhX7e6WIcWRhw=)\n(“Cosmos Health” or the “Company”) (NASDAQ:COSM)\n(https://www.globenewswire.com/Tracker?data=ty2BgeOcoXwpxlg1JJJFRtiJspWSiKNvaZCW8gbew5R3lr_3hgZAHX4sxzI90cLIx50bmHU9yhyqS_H47WaXdhuhwO7fz8NQvFNvOjV8Lbk=),\na diversified, vertically integrated global healthcare group, today announced\nthe U.S. launch of Oliv18™, further expanding its science-driven 18 Series\nnutraceutical platform into cardiovascular and antioxidant categories.\n\n\n\nScientific Background \nOliv18™ is formulated with a whole olive polyphenol extract derived from the\nfruit and leaf of olive trees cultivated in the Moroccan stretch of the\nSaharan Desert. The growing conditions include:\n* Arid temperatures of ≥140°F (60° C) in direct sun, with rocky terrain\n* Low water reserves and high water salinity\n* Thermo-evaporative conditions activate Phenylalanine Ammonia Lyase (PAL),\nwhich increases polyphenol synthesis in the olive tree\n\n\nThe extract is USDA and EU organic certified, produced using a 100%\nsolvent-free process, free from any hydrolysis or waste-water processing, and\nstandardized to hydroxytyrosol and oleuropein — the two key representative\nactives from the olive fruit and leaf respectively. Hydroxytyrosol is the most\nstudied polyphenol in olive oil, characterised by efficient absorption and\nrecognised as the highest Oxygen Radical Absorbance Capacity (ORAC)\npolyphenol, and exclusive to olives, olive oil, and wine.\n\nIt is estimated that a single 250 mg daily dose of Oliv18™ delivers\npolyphenols equivalent to approximately 11 teaspoons of good quality extra\nvirgin olive oil — the quantity associated with Mediterranean consumption\npatterns — and meets European Food Safety Authority’s (EFSA) 5 mg/day\nhydroxytyrosol minimum dose for protection against LDL oxidation.\n\nOliv18™ — Product Profile\n\n What it is         A whole olive polyphenol supplement                                             \n Source             Olive fruit and leaf — Moroccan Saharan desert                                  \n Certification      USDA & EU organic certified                                                     \n How it's made      100% solvent-free — no hydrolysis, no waste-water processing                    \n Key actives        11% total polyphenols — including 7% oleuropein and 3% hydroxytyrosol           \n Daily dose         250 mg per day (clinically studied serving size)                                \n EFSA               Meets EFSA's 5 mg/day hydroxytyrosol minimum dose for LDL oxidation protection  \n Daily equivalent   ~11 tsp of good quality extra virgin olive oil                                  \n Available formats  Capsules                                                                        \n\nMarket Opportunity \nOliv18™ addresses two significant and growing categories in consumer health\n— cardiovascular wellness and antioxidant protection — driven by aging\ndemographics, rising awareness of preventive wellness, and increasing consumer\ndemand for evidence-backed natural solutions.\n\nIn the United States, the cardiovascular health supplements market was\nestimated at $2.11 billion in 2024 and is projected to reach $3.27 billion by\n2030 (Grand View Research\n(https://www.globenewswire.com/Tracker?data=YSgomRXWwxkUvtADU5Ql8jqolaadQbFrBYcSJvLFXJ2_TgMOLlXJmWrFORTjV_4DUP5K0H3s_KFxxeuLo1ekFPYEm7F00pqVmU_aXF0cLktsDp-KqNLKzld-vfHFfaMUDCpgDapsEFMI005qZSoLXELPF4tH5I_U9kt5RLKxqfFrJcX5f5gK2b6M0eqtC1ZKHeISa7w200x_AP-e6F4otQ==)),\nwith the U.S. antioxidants market valued at $1.66 billion in 2025 and\nprojected to nearly double to $3.18 billion by 2035 (Precedence Research\n(https://www.globenewswire.com/Tracker?data=a33jd-ZZRZf1A-Yd_5a_1-bY9_xBFgscRMoIwg9oe6FetQYAtWNgQr6y2N556Iiq0_JMVJwdNA3iwIIrdeDR2OALI1bwuz_cuMWijO3wHc65_TirZmX0yzzcv1uzdSJwPQW3w7iVJ-X7X4E8yoiXmw==)).\nGlobally, the two categories are projected to reach $25.39 billion and $8.38\nbillion respectively by 2035 (SNS Insider\n(https://www.globenewswire.com/Tracker?data=QG1r8lLIUnzP89LUExqFDotbTpQr2kNRLJf1XCoCwKHh0fVq2LBF4IcHLGkM5_udtJpBwse40il6R13EVCwf-wUEk639FjMvjynJdzPTmnhLXq4CRMKX7AWXh6B8knoDGRRr72Gx3N_DjuZQa4UeyvUKDbvsvL5MpRLMLkBym60=);\nPrecedence Research\n(https://www.globenewswire.com/Tracker?data=a33jd-ZZRZf1A-Yd_5a_16UJByFsDyClBk6vm62_gd3ysrohDT6j1PYSBHlcO2wVLKnpZd6Zj3Qr6dC7vgmOGt6C4wXYnsMHHKTMBuMoLEcRZPLiPgkOWld-XqZQmtgUGkBdP2b3L3XAsj70udG_yg==))\n— collectively exceeding $33 billion by 2035.\n\nGreg Siokas, CEO of Cosmos Health, stated: “Oliv18™ represents another\nimportant step in the continued expansion of our 18 Series platform and\nreflects our broader strategy of developing differentiated nutraceutical\nproducts built around clinically informed formulation approaches, premium\nsourcing, and science-driven positioning. We believe long-term growth within\nconsumer wellness increasingly favors products supported by scientific\nsubstantiation, quality-focused manufacturing, and evidence-based formulation\nstrategies. Oliv18™ further strengthens our ability to expand within large\nand growing wellness categories while continuing to broaden the reach of our\n18 Series portfolio.”\n\nAbout the 18 Series \nThe 18 Series is Cosmos Health's premium U.S. nutraceutical platform built\naround science-driven product development, clinically informed formulation\napproaches, and premium positioning within major consumer wellness categories.\nAll products are manufactured in the United States under applicable quality\nand regulatory standards. The Company is targeting a portfolio of 18\nscience-based nutraceutical products for the United States market.\n\nThese products are dietary supplements. These statements have not been\nevaluated by the Food and Drug Administration. These products are not intended\nto diagnose, treat, cure, or prevent any disease.\n\nAbout Cosmos Health Inc. \nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,\nwww.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn\n(https://www.globenewswire.com/Tracker?data=zxV22i_B6-VCQIomX3iwoa_tfc8tIEfjDv6iKESFBVYfAVwie5zARA61JPjpFwhKHVoG5PGjgXFpbu-htrk6qGNLai1dmD6kUKo3Zz0r0rTZVe4xlWQbkHqEmw0Yv47E)\nand X\n(https://www.globenewswire.com/Tracker?data=CozEtOc6rr5n1cA6CFN4woT23GWWpxvyoISL4uudOkIFhBavBIMDpV_hY4xrt2-iwrL3ZYF0iiQETEaSCLnGTFoSJsitKLMBF7pjyruXTYY=).\n\nForward-Looking Statements \nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas “believes,” “expects,” “anticipates,” “intends,”\n“projects,” “estimates,” “plans,” and similar expressions, or\nfuture or conditional verbs such as “will,” “should,” “would,”\n“may,” and “could,” generally identify forward-looking statements,\nalthough not all forward-looking statements contain these words. These\nstatements involve risks and uncertainties that may individually or materially\naffect the matters discussed herein for a variety of reasons outside the\nCompany’s control, including, but not limited to: the Company’s ability to\nraise sufficient financing to implement its business plan; the effectiveness\nof its digital asset strategies, including accumulation and yield-generating\nactivities; the impact of the war in Ukraine and ongoing conflicts in the\nMiddle East and other regions on the Company’s business, operations, and the\neconomy in general; the Company’s ability to successfully develop and\ncommercialize its proprietary products and technologies; changes in interest\nrates; changes in foreign currency exchange rates, commodity or other price\ninflation and deflation; our ability to issue debt on terms and at rates\nacceptable to us; the impact and expected outcome of investigations,\ninquiries, claims, and litigation; the challenges of operating in\ninternational markets; the adequacy of insurance coverage; the effect of\naccounting charges and of adopting certain accounting standards; the impact of\nlegal and regulatory changes, including changes to tax laws and regulations;\nguidance for fiscal 2026 and beyond and financial outlook. Forward-looking\nstatements are based on currently available information and our current\nassumptions, expectations and projections about future events. You should not\nrely on our forward-looking statements. These statements are not guarantees of\nfuture performance and are subject to future events, risks and uncertainties\n– many of which are beyond our control, dependent on the actions of third\nparties, or currently unknown to us – as well as potentially inaccurate\nassumptions that could cause actual results to differ materially from our\nhistorical experience and our expectations and projections. These risks and\nuncertainties include, but are not limited to, those described from time to\ntime in our periodic reports filed with the SEC and available at the SEC’s\nwebsite (www.sec.gov). There also may be other factors that we cannot\nanticipate or that are not described herein, generally because we do not\ncurrently perceive them to be material. Such factors could cause results to\ndiffer materially from our expectations. Forward-looking statements speak only\nas of the date they are made, and we do not undertake to update these\nstatements other than as required by law. You are advised, however, to review\nany further disclosures we make on related subjects in our filings with the\nSecurities and Exchange Commission and in our other public statements.\n\nInvestor Relations Contact: \nBDG Communications \ncosm@bdgcommunications.com\n\nPhotos accompanying this announcement are available at \nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/debbdcf4-2485-45ec-8ac0-7dbfbf0959d1\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/cc6cb70a-e476-4105-b089-8ec0114ee3a1","article_body_html":"","raw_payload":{"data":{"id":"nGNEmHSCb","title":"Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories","author":"Globe Newswire","ticker":"COSM","created":"2026-06-05T13:25:00.313Z","tickers":["COSM"],"exchange":"NASDAQ","article_body":"Science-backed, USDA and EU-certified, whole olive tree supplement for two\nmajor wellness categories — rapidly growing global market projected to\nexceed $33 billion\n* Oliv18™ expands the 18 Series with a USDA and EU organic certified, 100%\nsolvent-free, whole olive polyphenol formulation from the Moroccan Saharan\ndesert\n* Hydroxytyrosol — the key active in Oliv18™ — is the highest ORAC\npolyphenol\n* A single 250 mg daily dose meets EFSA's 5 mg/day hydroxytyrosol minimum dose\nfor protection against LDL oxidation\n* A single daily dose equivalent to approximately 11 teaspoons of good quality\nextra virgin olive oil — compared to an average of half a teaspoon per day\nin the U.S.\n* Targeting the multibillion cardiovascular health and antioxidant markets,\ninitially in the United States and globally thereafter — within a combined\nglobal market landscape projected to exceed $33 billion by 2035\nCHICAGO, June 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.\n(https://www.globenewswire.com/Tracker?data=XjivXZ2iXwdVaNMLztXns3ZQYWrVdoQsE5h2TGn-I4CNkJE4fWFyLPRemCeOIHc400Zrqfpt5vFr4x5cyEsMjmYXjtZ2-9RhX7e6WIcWRhw=)\n(“Cosmos Health” or the “Company”) (NASDAQ:COSM)\n(https://www.globenewswire.com/Tracker?data=ty2BgeOcoXwpxlg1JJJFRtiJspWSiKNvaZCW8gbew5R3lr_3hgZAHX4sxzI90cLIx50bmHU9yhyqS_H47WaXdhuhwO7fz8NQvFNvOjV8Lbk=),\na diversified, vertically integrated global healthcare group, today announced\nthe U.S. launch of Oliv18™, further expanding its science-driven 18 Series\nnutraceutical platform into cardiovascular and antioxidant categories.\n\n\n\nScientific Background \nOliv18™ is formulated with a whole olive polyphenol extract derived from the\nfruit and leaf of olive trees cultivated in the Moroccan stretch of the\nSaharan Desert. The growing conditions include:\n* Arid temperatures of ≥140°F (60° C) in direct sun, with rocky terrain\n* Low water reserves and high water salinity\n* Thermo-evaporative conditions activate Phenylalanine Ammonia Lyase (PAL),\nwhich increases polyphenol synthesis in the olive tree\n\n\nThe extract is USDA and EU organic certified, produced using a 100%\nsolvent-free process, free from any hydrolysis or waste-water processing, and\nstandardized to hydroxytyrosol and oleuropein — the two key representative\nactives from the olive fruit and leaf respectively. Hydroxytyrosol is the most\nstudied polyphenol in olive oil, characterised by efficient absorption and\nrecognised as the highest Oxygen Radical Absorbance Capacity (ORAC)\npolyphenol, and exclusive to olives, olive oil, and wine.\n\nIt is estimated that a single 250 mg daily dose of Oliv18™ delivers\npolyphenols equivalent to approximately 11 teaspoons of good quality extra\nvirgin olive oil — the quantity associated with Mediterranean consumption\npatterns — and meets European Food Safety Authority’s (EFSA) 5 mg/day\nhydroxytyrosol minimum dose for protection against LDL oxidation.\n\nOliv18™ — Product Profile\n\n What it is         A whole olive polyphenol supplement                                             \n Source             Olive fruit and leaf — Moroccan Saharan desert                                  \n Certification      USDA & EU organic certified                                                     \n How it's made      100% solvent-free — no hydrolysis, no waste-water processing                    \n Key actives        11% total polyphenols — including 7% oleuropein and 3% hydroxytyrosol           \n Daily dose         250 mg per day (clinically studied serving size)                                \n EFSA               Meets EFSA's 5 mg/day hydroxytyrosol minimum dose for LDL oxidation protection  \n Daily equivalent   ~11 tsp of good quality extra virgin olive oil                                  \n Available formats  Capsules                                                                        \n\nMarket Opportunity \nOliv18™ addresses two significant and growing categories in consumer health\n— cardiovascular wellness and antioxidant protection — driven by aging\ndemographics, rising awareness of preventive wellness, and increasing consumer\ndemand for evidence-backed natural solutions.\n\nIn the United States, the cardiovascular health supplements market was\nestimated at $2.11 billion in 2024 and is projected to reach $3.27 billion by\n2030 (Grand View Research\n(https://www.globenewswire.com/Tracker?data=YSgomRXWwxkUvtADU5Ql8jqolaadQbFrBYcSJvLFXJ2_TgMOLlXJmWrFORTjV_4DUP5K0H3s_KFxxeuLo1ekFPYEm7F00pqVmU_aXF0cLktsDp-KqNLKzld-vfHFfaMUDCpgDapsEFMI005qZSoLXELPF4tH5I_U9kt5RLKxqfFrJcX5f5gK2b6M0eqtC1ZKHeISa7w200x_AP-e6F4otQ==)),\nwith the U.S. antioxidants market valued at $1.66 billion in 2025 and\nprojected to nearly double to $3.18 billion by 2035 (Precedence Research\n(https://www.globenewswire.com/Tracker?data=a33jd-ZZRZf1A-Yd_5a_1-bY9_xBFgscRMoIwg9oe6FetQYAtWNgQr6y2N556Iiq0_JMVJwdNA3iwIIrdeDR2OALI1bwuz_cuMWijO3wHc65_TirZmX0yzzcv1uzdSJwPQW3w7iVJ-X7X4E8yoiXmw==)).\nGlobally, the two categories are projected to reach $25.39 billion and $8.38\nbillion respectively by 2035 (SNS Insider\n(https://www.globenewswire.com/Tracker?data=QG1r8lLIUnzP89LUExqFDotbTpQr2kNRLJf1XCoCwKHh0fVq2LBF4IcHLGkM5_udtJpBwse40il6R13EVCwf-wUEk639FjMvjynJdzPTmnhLXq4CRMKX7AWXh6B8knoDGRRr72Gx3N_DjuZQa4UeyvUKDbvsvL5MpRLMLkBym60=);\nPrecedence Research\n(https://www.globenewswire.com/Tracker?data=a33jd-ZZRZf1A-Yd_5a_16UJByFsDyClBk6vm62_gd3ysrohDT6j1PYSBHlcO2wVLKnpZd6Zj3Qr6dC7vgmOGt6C4wXYnsMHHKTMBuMoLEcRZPLiPgkOWld-XqZQmtgUGkBdP2b3L3XAsj70udG_yg==))\n— collectively exceeding $33 billion by 2035.\n\nGreg Siokas, CEO of Cosmos Health, stated: “Oliv18™ represents another\nimportant step in the continued expansion of our 18 Series platform and\nreflects our broader strategy of developing differentiated nutraceutical\nproducts built around clinically informed formulation approaches, premium\nsourcing, and science-driven positioning. We believe long-term growth within\nconsumer wellness increasingly favors products supported by scientific\nsubstantiation, quality-focused manufacturing, and evidence-based formulation\nstrategies. Oliv18™ further strengthens our ability to expand within large\nand growing wellness categories while continuing to broaden the reach of our\n18 Series portfolio.”\n\nAbout the 18 Series \nThe 18 Series is Cosmos Health's premium U.S. nutraceutical platform built\naround science-driven product development, clinically informed formulation\napproaches, and premium positioning within major consumer wellness categories.\nAll products are manufactured in the United States under applicable quality\nand regulatory standards. The Company is targeting a portfolio of 18\nscience-based nutraceutical products for the United States market.\n\nThese products are dietary supplements. These statements have not been\nevaluated by the Food and Drug Administration. These products are not intended\nto diagnose, treat, cure, or prevent any disease.\n\nAbout Cosmos Health Inc. \nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,\nwww.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn\n(https://www.globenewswire.com/Tracker?data=zxV22i_B6-VCQIomX3iwoa_tfc8tIEfjDv6iKESFBVYfAVwie5zARA61JPjpFwhKHVoG5PGjgXFpbu-htrk6qGNLai1dmD6kUKo3Zz0r0rTZVe4xlWQbkHqEmw0Yv47E)\nand X\n(https://www.globenewswire.com/Tracker?data=CozEtOc6rr5n1cA6CFN4woT23GWWpxvyoISL4uudOkIFhBavBIMDpV_hY4xrt2-iwrL3ZYF0iiQETEaSCLnGTFoSJsitKLMBF7pjyruXTYY=).\n\nForward-Looking Statements \nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas “believes,” “expects,” “anticipates,” “intends,”\n“projects,” “estimates,” “plans,” and similar expressions, or\nfuture or conditional verbs such as “will,” “should,” “would,”\n“may,” and “could,” generally identify forward-looking statements,\nalthough not all forward-looking statements contain these words. These\nstatements involve risks and uncertainties that may individually or materially\naffect the matters discussed herein for a variety of reasons outside the\nCompany’s control, including, but not limited to: the Company’s ability to\nraise sufficient financing to implement its business plan; the effectiveness\nof its digital asset strategies, including accumulation and yield-generating\nactivities; the impact of the war in Ukraine and ongoing conflicts in the\nMiddle East and other regions on the Company’s business, operations, and the\neconomy in general; the Company’s ability to successfully develop and\ncommercialize its proprietary products and technologies; changes in interest\nrates; changes in foreign currency exchange rates, commodity or other price\ninflation and deflation; our ability to issue debt on terms and at rates\nacceptable to us; the impact and expected outcome of investigations,\ninquiries, claims, and litigation; the challenges of operating in\ninternational markets; the adequacy of insurance coverage; the effect of\naccounting charges and of adopting certain accounting standards; the impact of\nlegal and regulatory changes, including changes to tax laws and regulations;\nguidance for fiscal 2026 and beyond and financial outlook. Forward-looking\nstatements are based on currently available information and our current\nassumptions, expectations and projections about future events. You should not\nrely on our forward-looking statements. These statements are not guarantees of\nfuture performance and are subject to future events, risks and uncertainties\n– many of which are beyond our control, dependent on the actions of third\nparties, or currently unknown to us – as well as potentially inaccurate\nassumptions that could cause actual results to differ materially from our\nhistorical experience and our expectations and projections. These risks and\nuncertainties include, but are not limited to, those described from time to\ntime in our periodic reports filed with the SEC and available at the SEC’s\nwebsite (www.sec.gov). There also may be other factors that we cannot\nanticipate or that are not described herein, generally because we do not\ncurrently perceive them to be material. Such factors could cause results to\ndiffer materially from our expectations. Forward-looking statements speak only\nas of the date they are made, and we do not undertake to update these\nstatements other than as required by law. You are advised, however, to review\nany further disclosures we make on related subjects in our filings with the\nSecurities and Exchange Commission and in our other public statements.\n\nInvestor Relations Contact: \nBDG Communications \ncosm@bdgcommunications.com\n\nPhotos accompanying this announcement are available at \nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/debbdcf4-2485-45ec-8ac0-7dbfbf0959d1\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/cc6cb70a-e476-4105-b089-8ec0114ee3a1"},"type":"article","timestamp":"2026-06-05T13:25:00.419945443Z","server_sent_at_ms":1780665900419},"received_at":"2026-06-05T13:25:00.472Z","source_url":null},"analysis":{"id":"45791","press_release_id":"56365","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Cosmos Health launched Oliv18 in the U.S., a USDA and EU organic-certified whole olive polyphenol supplement targeting cardiovascular and antioxidant wellness.\n\nThe product is part of the company's 18 Series platform, featuring a solvent-free extract from Moroccan Saharan olives with a daily dose equivalent to 11 teaspoons of extra virgin olive oil.\n\nManagement cites a combined global market opportunity exceeding $33 billion by 2035, driven by aging demographics and demand for evidence-backed natural solutions.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Cosmos Health expands U.S. nutraceutical footprint with new olive-based supplement Oliv18."},"keyFigures":{"customDimensions":{"daily_dose_mg":250,"global_market_size_2035":"$33 billion","olive_oil_equivalent_tsp":11,"hydroxytyrosol_min_dose_mg":5,"us_antioxidant_market_2025":"$1.66 billion","us_antioxidant_market_2035":"$3.18 billion","us_cardiovascular_market_2024":"$2.11 billion","us_cardiovascular_market_2030":"$3.27 billion"}},"quotedText":"Oliv18™ represents another important step in the continued expansion of our 18 Series platform and reflects our broader strategy of developing differentiated nutraceutical products built around clinically informed formulation approaches, premium sourcing, and science-driven positioning.","namedEntities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["Oliv18","18 Series","Sky Premium Life","Mediterranation","bio-bebe","C-Sept","C-Scrub"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM","relationship":"filer"},{"name":"Cana Laboratories S.A.","relationship":"subsidiary"},{"name":"ZipDoctor, Inc.","relationship":"subsidiary"},{"name":"Grand View Research","relationship":"market research source"},{"name":"Precedence Research","relationship":"market research source"},{"name":"SNS Insider","relationship":"market research source"},{"name":"European Food Safety Authority","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"$33 billion","context":"combined global market landscape for cardiovascular and antioxidant categories by 2035"},{"amount":"$2.11 billion","context":"U.S. cardiovascular health supplements market in 2024"},{"amount":"$3.27 billion","context":"projected U.S. cardiovascular health supplements market by 2030"},{"amount":"$1.66 billion","context":"U.S. antioxidants market in 2025"},{"amount":"$3.18 billion","context":"projected U.S. antioxidants market by 2035"},{"amount":"$25.39 billion","context":"global cardiovascular health supplements market by 2035"},{"amount":"$8.38 billion","context":"global antioxidants market by 2035"}]},"materialImpact":{"score":2,"reasoning":"Launch of a new nutraceutical product (Oliv18) into the U.S. market. While it expands the company's portfolio and targets a large addressable market, it is a routine operational expansion for a diversified healthcare group, not a binary event or major M&A."},"tickerRelevance":{"others":[],"primary":"COSM"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"product_launch","sectorWeight":"healthcare_nutraceuticals","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Cosmos Health launched Oliv18 in the U.S., a USDA and EU organic-certified whole olive polyphenol supplement targeting cardiovascular and antioxidant wellness.\n\nThe product is part of the company's 18 Series platform, featuring a solvent-free extract from Moroccan Saharan olives with a daily dose equivalent to 11 teaspoons of extra virgin olive oil.\n\nManagement cites a combined global market opportunity exceeding $33 billion by 2035, driven by aging demographics and demand for evidence-backed natural solutions.","key_figures":{"customDimensions":{"daily_dose_mg":250,"global_market_size_2035":"$33 billion","olive_oil_equivalent_tsp":11,"hydroxytyrosol_min_dose_mg":5,"us_antioxidant_market_2025":"$1.66 billion","us_antioxidant_market_2035":"$3.18 billion","us_cardiovascular_market_2024":"$2.11 billion","us_cardiovascular_market_2030":"$3.27 billion"}},"named_entities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["Oliv18","18 Series","Sky Premium Life","Mediterranation","bio-bebe","C-Sept","C-Scrub"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM","relationship":"filer"},{"name":"Cana Laboratories S.A.","relationship":"subsidiary"},{"name":"ZipDoctor, Inc.","relationship":"subsidiary"},{"name":"Grand View Research","relationship":"market research source"},{"name":"Precedence Research","relationship":"market research source"},{"name":"SNS Insider","relationship":"market research source"},{"name":"European Food Safety Authority","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"$33 billion","context":"combined global market landscape for cardiovascular and antioxidant categories by 2035"},{"amount":"$2.11 billion","context":"U.S. cardiovascular health supplements market in 2024"},{"amount":"$3.27 billion","context":"projected U.S. cardiovascular health supplements market by 2030"},{"amount":"$1.66 billion","context":"U.S. antioxidants market in 2025"},{"amount":"$3.18 billion","context":"projected U.S. antioxidants market by 2035"},{"amount":"$25.39 billion","context":"global cardiovascular health supplements market by 2035"},{"amount":"$8.38 billion","context":"global antioxidants market by 2035"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-05T13:26:26.939Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"product_launch","sectorWeight":"healthcare_nutraceuticals","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":86456,"modelName":"george-droid-qwen-72b"}}